AbCellera Reports Q3 2026 Business Results investors.abcellera.com/news/news-rele…
AbCellera
Verified account This account is verified. Learn more@AbCelleraBio
AbCellera is clinical-stage biotech company focused developing antibody-based medicines in the areas of endocrinology, women’s health, immunology and oncology
88 Following 8K Followers 448 Posts
Latest posts 5
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026 investors.abcellera.com/news/news-rele…
AbCellera to Present at Upcoming Investor Conferences in November 2026 investors.abcellera.com/news/news-rele…
Visit our poster at The Menopause Society 2026 Annual Meeting. We will be presenting Phase 1/2 results on ABCL635, an investigational, potential best-in-class antibody drug for the non-hormonal treatment of vasomotor symptoms.
Read more about ABCL635 here:
abcellera.com/pipeline/abcl6…
Read more about ABCL635 here:
abcellera.com/pipeline/abcl6…
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting investors.abcellera.com/news/news-rele…
